Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

Also called NCT01624142

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 300 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01624142
  • EudraCT 2011-005400-15
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Brazil, Canada, Czechia, France, Greece, Hong Kong SAR China, Israel, Italy, Japan, Lebanon, Netherlands, New Zealand, South Africa, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01624142. Allocation not applicable; no masking; primary purpose treatment. Start 2012-06-01 (actual); primary completion 2018-05-11 (actual). Results posted on 2019-01-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
Acronym
TAUSSIG
Intervention (Biological)
Evolocumab
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01624142
Content hash
96ced22e9437e2551c3d392c02a38ec928061259f08c20c0815c6c3315884994